Highlights of the society for immunotherapy of cancer (SITC) 27th annual meeting-Reference-Cited by-同舟云学术

Highlights of the society for immunotherapy of cancer (SITC) 27th annual meeting

Published:2013-05-29 Issue:1 Volume:1 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Stroncek David F,Melief Cornelis JM,Castiello Luciano,Cesano Alessandra,Cheever Martin A,Civini Sara,Comin-Anduix Begonya,Gajewski Thomas F,Greenberg Philip D,Kalinski Pawel,Kaufman Howard L,Kershaw Michael H,Khleif Samir N,Marincola Francesco,Merritt William,Munn David H,Powell Daniel J,Restifo Nicholas P,Rosenberg Steven A,Puri Raj K,Streicher Howard,Szalay Aladar A,Yee Cassian,Zitvogel Laurence,Ribas Antoni

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/2051-1426-1-4.pdf

Reference64 articles.

1. Schreiber RD, Old LJ, Smyth MJ: Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011, 331: 1565-1570.

2. Szajnik M, Czystowska M, Szczepanski MJ, Mandapathil M, Whiteside TL: Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLoS One. 2010, 5: e11469-

3. Johnson TS, Munn DH: Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance. Immunol Invest. 2012, 41: 765-797.

4. Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ: Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest. 2004, 114: 280-290.

5. Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo T: PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 2004, 64: 1140-1145.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy improves disease prognosis by affecting the tumor microenvironment: A bibliometric study;Frontiers in Immunology;2022-10-06

2. Regulatory perspective on in vitro potency assays for human T cells used in anti-tumor immunotherapy;Cytotherapy;2018-05

3. Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells;Frontiers in Immunology;2016-03-09

4. Combining α-Radioimmunotherapy and Adoptive T Cell Therapy to Potentiate Tumor Destruction;PLOS ONE;2015-06-22

5. Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity;Frontiers in Immunology;2014-03-24